ResearcherZhejiang Provincial People's HospitalActive in the last 2 years

Peng Nan

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0009-6021-7723. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 6

Papers, trials and grants by year

2025: 2 papers

Papers 2

STYK1 as a targetable vulnerability enhances the efficacy of anti-PD-L1 therapy in pancreatic cancer. Co-author DOI 10.1007/s00535-025-02291-3 ↗
TSPAN15 sustains ITGB1 stability to block gemcitabine-induced ferroptosis in pancreatic ductal adenocarcinoma through the FAK/AKT/Mtor-gpx4 cascade. Co-author DOI 10.1016/j.redox.2025.103721 ↗

Closest collaborators

The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Zongting Gu · 2 shared papers, 2025 · strength 0.54
- Paper TSPAN15 sustains ITGB1 stability to block gemcitabine-induced ferroptosis in pancreatic ductal adenocarcinoma through t… DOI 10.1016/j.redox.2025.103721 ↗
- Paper STYK1 as a targetable vulnerability enhances the efficacy of anti-PD-L1 therapy in pancreatic cancer. DOI 10.1007/s00535-025-02291-3 ↗
Xiao Wang · 1 shared paper, 2025 · strength 0.28
- Paper TSPAN15 sustains ITGB1 stability to block gemcitabine-induced ferroptosis in pancreatic ductal adenocarcinoma through t… DOI 10.1016/j.redox.2025.103721 ↗
Ran Tao · 1 shared paper, 2025 · strength 0.28
- Paper TSPAN15 sustains ITGB1 stability to block gemcitabine-induced ferroptosis in pancreatic ductal adenocarcinoma through t… DOI 10.1016/j.redox.2025.103721 ↗
Ran Tao · 1 shared paper, 2025 · strength 0.26
- Paper STYK1 as a targetable vulnerability enhances the efficacy of anti-PD-L1 therapy in pancreatic cancer. DOI 10.1007/s00535-025-02291-3 ↗
Xiao Wang · 1 shared paper, 2025 · strength 0.26
- Paper STYK1 as a targetable vulnerability enhances the efficacy of anti-PD-L1 therapy in pancreatic cancer. DOI 10.1007/s00535-025-02291-3 ↗
Wei Wang · 1 shared paper, 2025 · strength 0.26
- Paper STYK1 as a targetable vulnerability enhances the efficacy of anti-PD-L1 therapy in pancreatic cancer. DOI 10.1007/s00535-025-02291-3 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.